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Both cellular iron deficiency and excess have adverse consequences. To maintain iron homeostasis, complex mechanisms have evolved to
regulate cellular and extracellular iron concentrations. Extracellular iron concentrations are controlled by a peptide hormone hepcidin, which
inhibits the supply of iron into plasma. Hepcidin acts by binding to and inducing the degradation of the cellular iron exporter, ferroportin, found in
sites of major iron flows: duodenal enterocytes involved in iron absorption, macrophages that recycle iron from senescent erythrocytes, and
hepatocytes that store iron. Hepcidin synthesis is in turn controlled by iron concentrations, hypoxia, anemia and inflammatory cytokines. The
molecular mechanisms that regulate hepcidin production are only beginning to be understood, but its dysregulation is involved in the pathogenesis
of a spectrum of iron disorders. Deficiency of hepcidin is the unifying cause of hereditary hemochromatoses, and excessive cytokine-stimulated
hepcidin production causes hypoferremia and contributes to anemia of inflammation.
© 2006 Elsevier Inc. All rights reserved.Keywords: Hepcidin; Iron; Hemochromatosis; Anemia of inflammamtion; Iron transport1. Iron is an essential trace element
Iron is an essential nutrient for nearly all animals and plants.
In mammals, iron is a component of heme in oxygen-
transporting and storage proteins (hemoglobin and myoglobin),
and a constituent of heme, iron–sulphur, and other iron-
containing centers in many redox enzymes, including enzymes
of the mitochondrial respiratory chain and ribonucleotide
reductase involved in deoxyribonucleotide synthesis. As these
iron-containing proteins have a vital role in energy metabolism,
cell proliferation [35] and DNA repair [42], severe cellular iron
deficiency results in inhibition of cell proliferation and even-
tually in cell death. On a systemic level [14], severe iron deficits
cause iron deficiency anemia which impairs oxygen delivery to
tissues and has adverse effects on cardiopulmonary function.
Iron is also an essential nutrient for nearly all microbes.
Mammals, whose cells divide much less frequently than
microbes do, take advantage of this vulnerability and use iron
starvation of infecting microbes as an important host defense
strategy. In response to infection, mammals sequester iron into
iron-binding proteins (e.g., ferritin, lactoferrin, siderocalin) and⁎ Corresponding author. Tel.: +1 310 825 6112.
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doi:10.1016/j.bbamcr.2006.03.014locations less accessible to most invading microbes (cytoplasm
of macrophages and hepatocytes) [29].
However, the sequestration of iron has adverse side effects
for the host, as it also reduces the delivery of iron to the nascent
erythrocytes in the bone marrow, and can become limiting for
hemoglobin synthesis. The cumulative deficit resulting from the
difference between hemoglobin synthesis and hemoglobin loss
through erythrocyte turnover is manifested as anemia of
inflammation (anemia of chronic disease).
Iron excess also has deleterious consequences [68]. Free iron
promotes generation of oxygen radicals by catalyzing the
Fenton reaction in which Fe2+ reacts with H2O2 or lipid
peroxides to generate highly reactive OHU or LOU and LOOU
radicals, which can damage lipid membranes, proteins and
nucleic acids. The pathological consequences of these processes
in hereditary and acquired forms of iron overload are discussed
elsewhere in this volume. The toxic effects of iron are avoided
through mechanisms that minimize free iron in the body under
normal circumstances. Any iron not incorporated as a functional
moiety of proteins is bound to transport or storage proteins in a
nontoxic form.
This review is focused on homeostatic and transport
mechanisms that have evolved to provide each cell with
adequate iron for its metabolic needs while maintaining
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(about 10–30 μM in humans). The review will also include a
discussion of genetic disorders of iron homeostasis that have
been essential for our understanding of the molecules and
processes involved.
2. Cellular iron homeostasis
Normally, nearly all plasma iron is bound to transferrin (Tf),
an abundant iron-binding protein. Most cells meet their iron
needs by taking up the Tf-bound iron from extracellular fluid
and plasma through transferrin receptor 1 (TfR1)-mediated
process [2]. Both diferric (Fe2Tf) and monoferric (FeTf)
transferrin traffic into endosomes where the low pH strips the
iron from the receptor–ligand complex. The TfR1-Tf is cycled
back to the plasma membrane, where at neutral pH, the iron-free
Tf is released back to plasma and TfR1 remains ready for the
next cycle of iron uptake. In the endosomes, released iron is
reduced from ferric to ferrous state and is transported across the
endosomal membrane into cytoplasm via divalent metal
transporter 1 (DMT1), a multispanning transmembrane protein
that acts as a proton–ferrous iron symporter, functioning
optimally under a positive pH gradient in the direction of iron
transport [43]. In the cytoplasm, a portion of the iron is stored
inside cytoplasmic ferritin, a spherical protein cage which can
accommodate up to 4500 iron atoms [76] at an effective
concentration that greatly exceeds the solubility of the ferrous
ion. This is made possible by the oxidation of ferrous iron inside
ferritin into a mineral form containing oxygen. The ferritin
molecule is assembled from 24 polypeptide subunits of two
ferritin types, H- and L-ferritin. H-ferritin has ferroxidase
activity that catalyzes the formation of the iron–oxygen mineral
product. Ferrous iron may enter and exit ferritin through pores
and/or may also be released from ferritin during its lysosomal
degradation.
The synthesis of proteins involved in cellular iron uptake and
storage, such as ferritin H and L chains, transferrin receptor 1
and some others, is modulated by the cellular iron levels. Under
conditions of low intracellular iron, iron regulatory proteins 1
and 2 (IRP-1 and -2) bind to iron regulatory elements (IRE) in
mRNAs encoding the regulated proteins [25]. The binding of
IRPs has differential effects on protein synthesis depending on
the location of the target IRE: binding of IRPs to 5′ IRE in
ferritin mRNAs inhibits translation but binding to 3′IRE in
TfR1 mRNAs increases their stability and concentration
[13,37,49]. Accordingly, in iron-deficient cells ferritin concen-
trations decline through turnover, and TfR1 concentrations
increase, setting up conditions that will correct the intracellular
iron deficiency and make more iron available for cellular
metabolic needs.
3. Systemic iron homeostasis
Complex mechanisms have evolved to maintain extracel-
lular iron concentrations in a relatively narrow range, and to
provide cells with adequate but not excessive iron for their
metabolic needs. Extracellular iron concentration is deter-mined by iron absorption in duodenum, recycling of iron
from aged erythrocytes by macrophages, iron storage by
hepatocytes, and iron utilization, mainly by the bone marrow
[4,8]. Iron is excreted by shedding of intestinal and skin
cells, and through minor blood loss in the intestine. In
principle, the shedding of epithelial cells could be used for
regulated iron excretion if these cells take up iron-transferrin
from plasma [16] but the capacity of this mechanism to
increase iron losses in response to increased iron load is
probably very limited, as indicated by the development of
progressive iron overload in patients who receive frequent
transfusions. The limited ability of humans to excrete iron
[22] means that total body iron balance is almost wholly
maintained through regulated absorption of iron from dietary
sources [46,74].
Total body iron in human adults amounts to approxi-
mately 3–4 g [8]. Two thirds of that is incorporated in the
heme moiety of hemoglobin found in erythroid precursors
and mature erythrocytes. Normal erythrocytes live around
120 days, and under average circumstance 20 ml of
erythrocytes (packed volume) containing a total of 20 mg
iron are destroyed each day. Thus, to maintain homeostasis,
20 mg of iron is required daily for production of hemoglobin
for new erythrocytes. Iron absorption from the diet, however,
supplies only 1–2 mg daily. The rest is derived by recycling
iron from senescent red blood cells. The process occurs in
splenic and other reticuloendothelial macrophages, which
phagocytose and lyse old and damaged red blood cells.
Heme is degraded by heme oxygenase and iron is recovered
and exported into plasma, ready for utilization by red blood
cell precursors and other cells. Even though recycled iron
accounts for most of the daily iron supply, the rate of
intestinal iron absorption is important in the long term. Over
many months, inadequate dietary supply results in iron
deficiency and anemia, whereas chronically increased iron
absorption due to genetic defects affecting iron sensing and
regulation, leads to iron overload diseases.
About a quarter of the total body iron (0.5–1.0 g) is stored
in macrophages and hepatocytes as a reserve which can be
easily mobilized for erythropoiesis. The stores, however, can
become depleted when iron uptake is less than iron usage and
loss, such as with decreased dietary iron uptake or excessive
blood loss. With stores depleted, erythropoiesis becomes iron-
restricted, eventually resulting in the development of iron
deficiency anemia. Iron overload disorders develop when iron
uptake (through diet, parenteral delivery or erythrocyte
transfusions) exceeds iron utilization and loss. If such iron
imbalance persists, excess iron is eventually deposited in the
liver and in other organs, such as the heart, pancreas, and the
pituitary gland. If untreated, tissue injury due to excess iron
will eventually lead organ dysfunction. In general, liver
damage (hepatic fibrosis, cirrhosis) occurs when liver iron
concentration are increased to more than 10-times normal, an
iron content associated with serum ferritin over 1000 ng/ml
[75]. It is much less clear whether the lesser degrees of iron
overload cause any clinical disease or accelerate coexisting
disease processes.
Fig. 1. Amino acid sequences of human (h), pig (p), rat (r), mouse (m), dog (d)
and zebrafish (z) hepcidin (HEP). The conserved cysteine framework is shaded.
692 T. Ganz, E. Nemeth / Biochimica et Biophysica Acta 1763 (2006) 690–6994. Molecular mechanisms of cellular iron import and
export
Beginning with absorption from the diet to reaching its sites
of utilization, iron needs to be transported across multiple cell
membranes. Specific transmembrane proteins mediate iron
import into and export out of the cells. Several modes of cellular
iron import have been described. Duodenal absorptive enter-
ocytes take up both heme and non-heme iron from the diet.
Heme transport is less well understood, but candidate intestinal
heme transporters have been described [73]. Inside the
enterocyte, iron is released from the heme by heme oxygenase
and is thought to be exported out of the cell by a common
pathway together with non-heme iron. Non-heme dietary iron is
in the insoluble Fe3+ form, and is first reduced to Fe2+, in part
by duodenal cytochrome b-like ferrireductase (Dcytb), and then
transported across the membrane by divalent metal transporter-
1 (DMT1), a proton/divalent metal symporter. DcytB appears to
be redundant in mice because its transgenic disruption has little
or no effect on iron absorption [24]. In contrast, selective
inactivation of DMT-1 in intestine of mice results in severe iron
deficiency anemia [23].
As described earlier, a common iron import mechanism is
through Tf-TfR1 cycle. Most plasma iron is destined for the
production of hemoglobin in erythroid precursors in the bone
marrow. After transferrin-bound iron is internalized through
TfR1, iron in erythroid endosomes is reduced by a ferrireduc-
tase Steap3 [59], and transported across the endosomal
membrane by DMT1 [12]. Disruptive mutations in either
DMT1 [12,47,66] or the erythroid ferrireductase [59] result in
defective iron utilization by red cell precursors. Transferrin-
mediated iron uptake is also used by most other cell types since
TfR1 is nearly ubiquitously expressed. The importance of this
mechanism is underlined by transgenic mouse models in which
inactivation of TfR1 results in embryonic death [39].
Certain cell types can take up iron by Tf-independent
mechanisms. Mice deficient in functional Tf develop severe
iron overload in nonhematopoietic tissues, such as liver and
pancreas [77] indicating that these tissues can take up iron by an
alternative mechanism. In addition, monocytes and macro-
phages can take up hemoglobin by haptoglobin-mediated
binding to hemoglobin scavenger receptor (CD163) [33]. This
pathway is particularly prominent in diseases with intravascular
hemolysis such as sickle cell anemia and thalassemia.
Additional uptake mechanisms may exist for iron sequestered
in ferritin or hemopexin, but the mechanisms have not been well
characterized. Finally, phagocytosis of senescent erythrocytes
by specialized macrophages constitutes an important indirect
iron uptake mechanism.
In contrast with multiple iron uptake mechanisms, only one
pathway for cellular iron export has been described to date. A
membrane multi-spanning channel ferroportin is found in all the
cell types exporting iron into plasma: duodenal enterocytes,
macrophages, hepatocytes, placental trophoblasts, and cells of
the central nervous system. Total ferroportin deficiency in mice
or zebrafish is embryonic lethal due to the lack of iron transfer
across the maternal–fetal interface [16]. Selective inactivationof ferroportin that spares the maternal–fetal interface allows
survival to birth but leads to iron trapping in enterocytes,
hepatocytes and macrophages in the face of severe systemic iron
deficiency, indicating the unique and non-redundant function of
ferroportin in cellular iron export.
Iron export by ferroportin and subsequent loading onto
transferrin also requires presence of multicopper oxidases
which convert Fe2+ to Fe3+. An abundant plasma protein
ceruloplasmin is involved in iron export from nonintestinal cells
and its homolog hephaestin aids iron export from intestinal
cells. Deficiency of ceruloplasmin in patients and mice also
leads to iron accumulation in macrophages, hepatocytes, as well
as cells of the CNS, resulting in iron-restricted erythropoiesis
and neurodegeneration [81]. Hephaestin deficiency results in
severe iron-deficiency anemia [3].
5. Hepcidin is the principal regulator of extracellular iron
concentration
Recently discovered peptide hormone hepcidin (Fig. 1) is the
key regulator of systemic iron homeostasis. Hepcidin is
produced in the liver, circulates in plasma and is excreted in
urine [32,62]. It is encoded by a small three-exon gene as a
preprohepcidin with a characteristic signal sequence and a furin
cleavage site preceding the mature hepcidin peptide. The active
form of the peptide is a 25 amino acid β-sheet hairpin stabilized
by four disulfide bonds. Hepcidin is found in vertebrates
including fish, and some species, including mouse, have
multiple hepcidin genes not all of which may be involved in
iron metabolism [41]. The structural similarity between hepcidin
and typical amphipathic antimicrobial peptides such as porcine
protegrins [27] suggests that hepcidin may have evolved as an
antimicrobial peptide that acquired a new function.
In mice, hepcidin deficiency due to disruption of a
neighboring gene resulted in iron overload similar to human
hereditary hemochromatosis [54] and in humans, disruption of
hepcidin gene causes the most severe form of iron overload—
juvenile hemochromatosis [71]. Conversely, overexpression of
hepcidin-1 (but not hepcidin-2) in transgenic mice caused
severe iron-deficiency anemia [41,55]. Similarly, dysregulated
overproduction of hepcidin by liver tumors in patients with type
1a glycogen storage disease caused iron-refractory anemia
which resolved only after the resection of the tumor, or after
liver transplantation [80]. Hepcidin is thus a negative regulator
of iron absorption, recycling and release from stores and the
Fig. 2. A model of hepcidin (hepc) regulation by iron. In the model, hemojuvelin
(HJV) and its putative receptor are the key regulators of hepcidin. Other
regulators include TfR2 and HFE. Soluble hemojuvelin inhibits hepcidin
production in vitro but its biological role remains to be established. The
inhibition of the shedding of soluble hemojuvelin by iron and the stabilization of
TfR2 by iron-transferrin suggest that these two molecules could participate in
iron sensing. TFs = transcription factors.
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iron and anemia. Both dietary and parenteral iron load induced
hepcidin mRNA in mice [50,65], and in humans, ingestion of a
single dose of 65 mg of iron increased urinary hepcidin several-
fold within hours [50]. It is not yet clear how iron (presumably
through transferrin saturation) regulates hepcidin production
and release. The best available information comes from genetic
lesions in patients and animal models where hepcidin
production is deficient in spite of iron overload.
6. Regulation of hepcidin by iron: lessons from hereditary
hemochromatosis
Hereditary hemochromatosis caused by homozygous dis-
ruption of HFE, transferrin receptor 2 (TfR2) and hemojuvelin
(HJV) is characterized by hepcidin deficiency in spite of
massive iron overload, indicating that all these molecules act as
direct or indirect regulators of hepcidin synthesis. Of these,
hemojuvelin appears to have the greatest impact on hepcidin
regulation because its disruption phenotypically completely
mimics homozygous disruption of the hepcidin gene itself, and
both result in the most severe form of hereditary hemochroma-
tosis, juvenile hemochromatosis [60,71]. Accordingly, patients
with HJV hemochromatosis had undetectable levels of urinary
hepcidin [60]. Untreated patients with juvenile hemochromato-
sis usually develop iron overload and damage to the liver,
endocrine glands, heart and other organs in their teens and
twenties, and both genders are affected more or less equally.
Humans and mice with homozygous HFE disruption have
hepatic hepcidin mRNA levels which are inappropriately low
for the degree of iron loading [1,9,48]. However, our
measurements of urinary hepcidin in untreated HFE patients
(submitted) indicate that hepcidin is not as severely decreased in
HFE hemochromatosis as it is in hemochromatosis due to
defects in hemojuvelin or TfR2 [51]. The HFE mutations indeed
cause a milder and less penetrant form of hemochromatosis,
with a later onset and less severe presentation in women.
Therefore, HFE is likely a modulator of signaling from the iron
sensor to hepcidin but is not essential for the function of this
pathway. Bone marrow transplantation experiments between
HFE-deficient and wild-type mice suggest that the effect of
HFE on hepcidin production may be mediated through
macrophages [44]. In contrast, the hemochromatosis due to
homozygous disruption of TfR2 is somewhat more severe [11],
and urinary hepcidin levels are very low [51]. TfR2 is
predominantly expressed in the liver and its levels are regulated
by transferrin saturation [28,70], making TfR2 a strong
candidate for an iron sensor (Fig. 2). Recently, a patient with
a very severe early onset form of hemochromatosis was found to
have mutations that disrupted both the HFE and TfR2 genes
[64], indicating that these genes may provide additive signals to
the iron-regulatory pathway.
7. Hemojuvelin is a key regulator of hepcidin
Hemojuvelin [60] belongs to the family of repulsive
guidance molecules (RGM) involved in neuronal differentia-tion, migration, and apoptosis [10,45,58,72]. However, unlike
other RGMs which are expressed in neural tissue, hemojuve-
lin is expressed predominantly in skeletal muscle, the liver
and the heart. One form of hemojuvelin is GPI-linked to the
membrane [82] and this form was shown to undergo cleavage
in cell culture, resulting in the release of the soluble
hemojuvelin into the medium [40,82]. The soluble form was
also detected in human sera [40] indicating that cleavage
occurs in vivo. Importantly, the cleavage of hemojuvelin in
vitro is inhibited by iron: increasing concentrations of Fe2Tf
or ferric ammonium citrate progressively suppressed the
release of soluble hemojuvelin from cells into the medium,
suggesting that hemojuvelin could be a part of the iron sensor
complex [40].
Hemojuvelin directly regulates hepcidin expression in vitro
[40]. Knockdown of hemojuvelin expression by siRNA in
Hep3B cells resulted in a decrease of hepcidin mRNA
expression showing that cellular hemojuvelin positively
regulated hepcidin mRNA expression. In contrast, the addition
of recombinant soluble hemojuvelin to primary human
hepatocytes suppressed hepcidin mRNA in a log-linear dose-
dependent manner, suggesting binding competition between
soluble and cell-associated hemojuvelin. Examination of the
global effect of soluble hemojuvelin on gene expression in
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highly selective, as hepcidin mRNA showed the largest change
of any transcript. We proposed that soluble and cell-associated
hemojuvelin reciprocally regulate hepcidin expression in
response to changes in extracellular or plasma iron concentra-
tion [40] (Fig. 2).
The mechanism of hemojuvelin action, however, is still
unclear. It likely involves interactions with other proteins, since
hemojuvelin lacks a cytoplasmic tail for direct signaling to the
cell interior, and other members of the RGM family (RGMa and
RGMb) function as receptor ligands. Both RGMa and RGMb
are co-receptors for BMP signaling [5], RGMa was also shown
to bind to neogenin, an N-CAM receptor, to regulate neuronal
survival [45,67]. Zhang et al. [82] reported that hemojuvelin
also interacts with neogenin in HEK293 cells overexpressing
HJV, and co-expression of the two proteins in HEK293 led to
increased cellular iron retention. It remains to be determined
whether hemojuvelin–neogenin interaction regulates hepcidin
expression, and if it affects iron homeostasis in vivo. Other
candidates for transmembrane receptors interacting with
hemojuvelin include the receptors of the TGFβ/BMP super-Fig. 3. (A) Hepcidin causes internalization of GFP-tagged ferroportin. A cluster of HE
treatment. (B) Hepcidin-induced ferroportin internalization leads to decreased cellulfamily [79]. Hemojuvelin was recently reported to act as a BMP
co-receptor, and the resulting signal transduction pathway was
shown to modulate hepcidin expression [26]. TGFβ and BMP
ligands were also independently shown to induce hepcidin
mRNA in hepatocyte cell lines [79]. Additionally, mice with
liver-specific knockout of SMAD4, a signaling adaptor used by
several receptors of the TGFβR family, developed hemochro-
matosis, supporting the important role of the TGFβR family in
iron homeostasis and hepcidin regulation [79]. However,
SMAD4 deficiency affects multiple hepatic transcripts and
results in a complex phenotype. Therefore, the specific role of
this pathway in hepcidin regulation remains to be defined.
8. Regulation of hepcidin by anemia and hypoxia
Anemia and hypoxemia suppress hepcidin production but the
molecular mechanisms are unknown. In animal models,
bleeding or PHZ-induced hemolysis in mice caused a decrease
in hepcidin mRNA levels [7,19,34,56], as did the exposure of
mice and rats to a hypoxic atmosphere [38,56]. Anemia could be
regulating hepcidin through tissue hypoxia (possibly throughK293 cells expressing GFP-tagged ferroportin is shown before and after hepcidin
ar iron efflux.
Fig. 4. Major iron flows are controlled by hepcidin–ferroportin interactions.
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directly regulate hepcidin gene expression) or indirectly by
stimulation of erythropoiesis and increased demand for iron,
resulting in decreased transferrin saturation which would
suppress hepcidin synthesis. Whichever the pathway, hepcidin
was found to be decreased in diseases with ineffective
erythropoiesis such as thalassemias [30,61] despite the con-
comitant iron overload, indicating a strong and dominant effect
of anemia over iron on hepcidin production. The consequent low
levels of hepcidin in these patients cause hyperabsorption of iron
and contribute to systemic iron overload with resulting organ
damage. In severe forms of thalassemia, the repeated blood
transfusions add to the iron burden but it is possible that even in
these patients the relative hepcidin deficiency exacerbates iron
toxicity by redistributing iron from the nontoxic macrophage
pool to other cell types and tissues where defenses against iron
toxicity may be less effective.
9. The mechanism of hepcidin action
The principal bioactivity of hepcidin is the rapid induction of
hypoferremia. Injection of a single dose of synthetic hepcidin in
mice caused a dramatic drop in serum iron already within 1 h,
and the effect persisted for up to 72 h [69]. In mice and
presumably also in humans, the effective concentrations of
hepcidin are in the 100–1000 nM range [52,69]. Hepcidin acts
by binding to the sole cellular iron exporter, ferroportin, and
causing its internalization and degradation (Fig. 3) [52], with
effective concentrations of hepcidin in the same 100–1000 nM
range as those required for the induction of hypoferremia in
vivo. As pointed out earlier, ferroportin is found in all the tissues
that export iron into plasma: basolateral membranes of duodenal
enterocytes, and the cell membranes of placental cells,
hepatocytes and macrophages [16]. In these locations, ferro-
portin is in a unique position to regulate the inflow of iron into
plasma from dietary or maternal sources, from hepatic stores
and from macrophages engaged in recycling senescent
erythrocytes.
The homeostatic loop involving hepcidin and ferroportin
maintains normal extracellular iron concentrations (Fig. 4). This
is best illustrated by considering the response of the system to
perturbations in extracellular iron concentration. When plasma
transferrin saturation rises, for example as a result of dietary iron
intake, it acts as a stimulus for hepcidin release. Increased
concentrations of hepcidin cause increased internalization of
ferroportin from the cell membrane and its subsequent
degradation, resulting in a greater inhibition of the iron influx
into plasma from the ferroportin-rich tissues. The ferroportin-
rich, iron-exporting tissues include macrophages that recycle
red blood cells (predominantly in the spleen and in the liver),
duodenal enterocytes that absorb dietary iron, and hepatocytes
storing iron. During pregnancy, fetal hepcidin also regulates the
transport of iron across the placenta form the mother to the
fetus. With decreased efflux of iron from all these tissue
sources, the small plasma iron pool is restored to normal by
continued utilization of iron, mainly for erythropoiesis. When
hepcidin production is increased by inflammation, the sameregulatory circuitry is responsible for inflammation-related
hypoferremia and anemia.
10. Inflammation, hepcidin and iron
It has been known for many decades that inflammation
alters iron metabolism by decreasing the iron content of
plasma (hypoferremia of inflammation). If inflammation is
sufficiently severe or chronic, a normocytic normochromic
anemia (anemia of chronic disease, anemia of inflammation)
eventually develops. Although this anemia resembles iron
deficiency anemia by developing in the setting of low plasma
iron, it differs from iron deficiency anemia by the presence of
stainable iron in bone marrow macrophages, and by elevated
serum ferritin—both indicative of adequate iron stores. The
molecular basis of these changes was only recently elucidated
and centers on the regulation of hepcidin by inflammation
[21]. Hepcidin production increases in inflammation, and
injections of turpentine, Freund's adjuvant or LPS were all
shown to increase hepatic hepcidin mRNA expression in mice
and rats [20,50,56]. In addition, increased urinary hepcidin
levels were seen in patients with infection and inflammatory
disorders [53] and infusion of LPS in healthy subjects also
resulted in rapid increase in urinary hepcidin [31]. Unlike iron
and hypoxia, molecular pathways of hepcidin regulation by
inflammation are better understood and primarily involve the
inflammatory cytokine interleukin-6 (IL-6). Treatment of
696 T. Ganz, E. Nemeth / Biochimica et Biophysica Acta 1763 (2006) 690–699primary hepatocytes with IL-6 in vitro, or injection of IL-6 in
mice or humans increased hepcidin production within hours
[50,53]. IL-1 also induced hepcidin in human hepatocytes but
this effect was dependent on the intermediate production of
IL-6. Tumor necrosis factor-α suppressed hepcidin synthesis
in human hepatocyte cell lines [50]. Experiments in mice
lacking IL-6 show that other cytokines, including IL-1, may
contribute to hepcidin induction during inflammation but it is
not certain whether the specific hepcidin-stimulatory cyto-
kines are the same in mice and humans [36].
Increased plasma hepcidin during inflammation induces
the internalization and degradation of ferroportin in macro-
phages, hepatocytes and duodenal enterocytes, thus trapping
iron in these cells and preventing the efflux of iron into
plasma. Within hours, the continued utilization of iron by
developing erythrocytes depletes the plasma iron compart-
ment, causing hypoferremia. Erythropoiesis, and more
specifically heme and hemoglobin synthesis become iron
limited, as evidenced by increased substitution of zinc for
iron during heme synthesis (zinc protoporphyrin). By
apparently unrelated mechanisms, inflammation also shortens
erythrocyte lifespan and the decreased erythrocyte supply and
increased erythrocyte loss lead to anemia. The hypoferremia
and anemia eventually turn off hepcidin production so that a
new setpoint is reached at a lower serum iron and blood
hemoglobin concentration.
11. Hereditary hemochromatosis
Hereditary hemochromatosis encompasses a genetically
and clinically heterogeneous group of disorders characterized
by increased and dysregulated iron absorption in the small
intestine [63]. The most common form of the disorder in
populations of Northern European ancestry is due to
mutations in the HFE gene (predominantly Cys282Tyr
homozygotes but also compound heterozygotes with
His63Asp). This form has a low clinical penetrance [6]
(higher in men than in women) but commonly causes
laboratory abnormalities including elevated serum ferritin,
elevated transferrin saturation, and elevated serum levels of
hepatic enzymes. Less commonly the disorder progresses to
cirrhosis, and can affect other organs including the pancreas,
the joints and the skin. The clinically most severe form of
hemochromatosis is referred to as juvenile hemochromatosis
because of its early age of onset in adolescents. Juvenile
hemochromatosis is most often due to homozygous or
compound heterozygous mutations in the HJV gene (encoding
hemojuvelin) and rarely due to homozygous mutations in the
HAMP gene (encoding hepcidin). Hemochromatosis due to
mutations in the TfR2 gene is relatively rare and appears to
have a moderate phenotype. Although large scale systematic
studies of hepcidin levels in patients with hemochromatosis
have not yet been reported, it is not unreasonable to expect
that the severity of the disease will correlate with hepcidin
levels, with more severe phenotypes manifesting more
complete hepcidin deficiency, corresponding to the loss of
hepcidin responsiveness to iron loading.In animal models, the central role of hepcidin deficiency in
hereditary hemochromatosis is underlined by the ability of
transgenic hepcidin to prevent iron overload in HFE −/− mice
[57]. From the therapeutic point of view, it is especially
encouraging that even in mice with HFE hemochromatosis and
established iron overload, tetracycline-induced transgenic
hepcidin expression led to the redistribution of iron from
hepatocytes to macrophages where iron maybe less toxic [78].
Although often included with hemochromatosis, mutations
in ferroportin most frequently give rise to a distinct disorder,
sometimes called “ferroportin disease”. In this autosomal
dominant disorder, iron is predominantly found in macro-
phages. Recent studies suggest that some mutations cause
ferroportin functional deficiency [17] due to mislocalization of
ferroportin molecules within the cell. This may be exacerbated
by multimerization of mutant with wild-type molecules,
resulting in mislocalization of the wild-type ferroportin [15].
Other mutations appear to generate functional ferroportin that is
resistant to the effect of hepcidin [15,17] and these may cause
true hemochromatosis with iron loading of the hepatocytes and
a phenotype similar to classical hemochromatosis due to HFE
mutations.
12. Summary and conclusions
It has been less than 5 years since the appearance of first
publications on hepcidin [32,62,65] and the first indication
that hepcidin could be involved in iron metabolism [65].
Building on older studies that defined the phenomenology of
the regulation of iron absorption and recycling, and more
recent work that identified the key iron transporters, the
identification of hepcidin as the long sought iron-regulatory
hormone greatly simplified our understanding of systemic
iron metabolism. It now appears that a single molecule,
hepcidin, is the “stores” regulator, the “erythropoietic”
regulator and the “inflammation” regulator of iron absorption
and recycling [18,56], and that hepcidin acts principally or
perhaps solely by causing the internalization and degradation
of its receptor/iron channel ferroportin [52]. The delineation
of the molecular determinants of the hepcidin–ferroportin
interaction is a worthwhile long-term goal that could facilitate
the development of hepcidin agonists and antagonists.
However, the many membrane-spanning segments that
comprise much of the ferroportin molecule make it unlikely
that its structure will be solved very soon.
Although we have learned much about how hepcidin
regulates iron transport (the efferent arc of the homeostatic
loop), we know very little about the afferent arc: how
hepcidin production and release are regulated by iron and
oxygen. The genetics of hereditary hemochromatosis points
to TfR2, hemojuvelin and HFE as components of the
regulatory pathways but it is by no means clear how these
(and likely other) components fit together. Neither is it
certain whether all of the hepcidin-regulating circuitry is
contained in the liver or whether remote oxygen or iron
sensors and circulating signals (perhaps soluble hemojuvelin)
contribute to hepcidin regulation. It is our hope that further
697T. Ganz, E. Nemeth / Biochimica et Biophysica Acta 1763 (2006) 690–699advances in the next few years will answer these questions
and lead to a more complete understanding of systemic iron
homeostasis.
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